Ro, a NYC-based healthcare technology company, completed a $500m Series D funding.
The round, which brought total funding since its founding in 2017 to $876m, was led by existing investors General Catalyst, FirstMark Capital and TQ Ventures, with participation from existing investors SignalFire, Torch Capital and BoxGroup as well as new investors Altimeter Capital, Baupost Group, Dragoneer Investment Group, ShawSpring Partners, Radcliff, and 776.
The company intends to use the funds to strengthen its vertically integrated primary care platform, expand its pharmacy distribution network, continue to enhance its proprietary EMR (the Ro Collaborative Care Center), build new capabilities such as remote patient monitoring with integrated devices, and broaden into additional treatment areas that leverage its diagnostic capabilities.
Led by Zachariah Reitano, Co-Founder & CEO, Ro is a healthcare technology company building a patient-centric healthcare system. The company’s integrated primary care platform powers a personalized, end-to-end healthcare experience from diagnosis, to delivery of medication, to ongoing care. With a nationwide provider network, in-home care API, and proprietary pharmacy distribution centers, Ro connects telehealth, diagnostics, and pharmacy services to provide high-quality, affordable healthcare without the need for insurance.
Since 2017, the company has facilitated more than six million digital healthcare visits in nearly every county in the United States, including 98% of primary care deserts.
The Series D round follows Ro’s acquisition of Workpath, a software platform that enables healthcare companies to offer on-demand, in-home care and diagnostic services with an API. The acquisition has allowed Ro to integrate virtual and in-person care on its own platform and offer these in-home capabilities to other healthcare companies.